IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Transcript
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
IOL Chemicals reported its highest-ever quarterly revenue of INR 619 crores in Q4 FY26 (up 17.4% YoY), with full-year revenue of INR 2,319 crores. EBITDA for the quarter improved significantly to INR 94 crores (margin 15.2%, up 251 bps YoY), while full-year EBITDA reached INR 290 crores (margin 12.4% vs 10.7% prior year). PAT grew 68% YoY to INR 53 crores in Q4. The company guided for FY27 revenue growth of around 15% with EBITDA margins of 14-14.5%. Management revealed plans for a greenfield project on 100 acres near Bhatinda with an estimated outlay of INR 1,200-1,400 crores over 4-5 years, funded through internal accruals at INR 200-250 crores annually. Ibuprofen contributes 62% of pharma revenue with 90-95% capacity utilization, while the non-Ibuprofen segment aims to increase export share to 25% in FY27.
The company demonstrated strong operational execution with margin improvement and capacity optimization. Management's medium-term guidance of 15% revenue growth and improving margins to 14%+ appears achievable given capacity utilization trends and new product expansion. The INR 1,200-1,400 crore greenfield capex will drive future growth but requires ongoing cash deployment.